Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Nov 8:2024.05.24.24307900.
doi: 10.1101/2024.05.24.24307900.

Disparities in dolutegravir utilisation in children, adolescents and young adults (0-24 years) living with HIV: An analysis of the IeDEA Paediatric West African cohort

Sophie Desmonde  1 , Joycelyn Dame  2 , Karen Malateste  3 , Agatha David  4 , Madeleine Amorissani-Folquet  5 , Sylvie N'Gbeche  6 , Mariam Sylla  7 , Elom Takassi  8 , François Tanoh Eboua  9 , Kouadio Kouakou  10 , Lehila Bagnan Tossa  11 , Caroline Yonaba  12 , Valériane Leroy  1 ; IeDEA Pediatric West African cohort
Affiliations

Disparities in dolutegravir utilisation in children, adolescents and young adults (0-24 years) living with HIV: An analysis of the IeDEA Paediatric West African cohort

Sophie Desmonde et al. medRxiv. .

Update in

Abstract

Introduction: We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.

Methods: We included all patients aged 0-24 years on ART from nine clinics in Côte d'Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by clinic and was defined as date of first DTG prescription; patients were followed up until database closure/death/loss to follow-up (LTFU, no visit ≥ 7 months), whichever came first. We computed the cumulative incidence function for DTG initiation; associated factors were explored in a shared frailty model, accounting for clinic heterogeneity.

Results: Since 2019, 3,350 patients were included; 47.2% were female; 78.9% had been on ART ≥ 12 months. Median baseline age was 12.5 years (Interquartile range[IQR]: 8.4-15.8). Median follow-up was 14 months (IQR: 7-22). The overall cumulative incidence of DTG initiation reached 22.7% (95% Confidence Interval (CI): 21.3-24.2) and 56.4% (95% CI: 54.4-58.4) at 12 and 24 months, respectively. In univariate analyses, those aged <5 years and females were overall less likely to switch. Adjusted on ART line and available viral load (VL) at baseline, females >10 years were less likely to initiate DTG compared to males of the same age (adjusted Hazard Ratio [HR] among 10-14 years: 0.62, 95% CI: 0.54-0.72; among ≥15 years: 0.43, 95% CI: 0.36-0.50), as were those with detectable VL (> 50 copies/mL) compared to those in viral suppression (aHR: 0.86, 95% CI: 0.77-0.97) and those on protease inhibitors compared to those on non-nucleoside reverse-transcriptase inhibitors (aHR after 12 months of roll-out: 0.75, 95% CI: 0.65-0.86).

Conclusion: Paediatric DTG uptake was incomplete and unequitable in West African settings: DTG use was least likely in children <5years, females ≥ 10 years and those with detectable viral load. Maintained monitoring and support of treatment practices is required to better ensure universal and equal uptake.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS The authors declare that they have no competing interests.

Figures

Figure 1 –
Figure 1 –
Overall 24-month cumulative incidence function of DTG initiation among the 3,350 children, adolescents and young adults living with HIV and enrolled in the IeDEA pediatric West African sites rolling-out DTG
Figure 2 –
Figure 2 –
24-month cumulative incidence function of DTG initiation by clinic among the 3,350 children, adolescents and young adults living with HIV and enrolled in the IeDEA pediatric West African clinics rolling-out DTG
Figure 3 –
Figure 3 –
24-month cumulative incidence function of DTG initiation among the 3,350 children, adolescents and young adults living with HIV and enrolled in the IeDEA pediatric West African clinics rolling-out DTG by sex (A), baseline age (B), baseline viral load (C) and baseline ART regimen (D).
See this image and copyright information in PMC

References

    1. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. Geneva: World Health Organization; 2016. - PubMed
    1. Phillips AN, Cambiano V, Nakagawa F, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5:e146–54. doi: 10.1016/S2352-3018(17)30190-X - DOI - PMC - PubMed
    1. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379:979–81. doi: 10.1056/NEJMc1807653 - DOI - PMC - PubMed
    1. World Health Organisation. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Geneva, Switzerland: 2018.
    1. Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381:827–40. doi: 10.1056/NEJMoa1905230 - DOI - PMC - PubMed

Publication types